Cardiac resynchronization therapy defibrillators reduce hospitalizations among patients with mild heart failure, according to a study published in the New England Journal of Medicine. These implanted devices try to slow heart failure by correcting inefficient heartbeats, in contrast with standard defibrillators, which deliver a jolt after the heart stops. The resynchronizing defibrillators cost approximately $30,000 each.
After an average of 2.4 years, about 17.2 percent of study patients with a resynchronizing defibrillator had been hospitalized or intensively treated for heart failure, or had died. The corresponding figure for patients with a standard defibrillator was 25.3 percent. About 7 percent of patients in each group died.
The four-year study of 1,820 patients was funded by Boston Scientific.
In an accompanying editorial, University of Pennsylvania cardiologist Mariell Jessup noted that based on study results, 12 patients would need to be treated to prevent one heart-failure event.